Metastatic Renal Cell Carcinoma Clinical Trials

25 recruiting

Metastatic Renal Cell Carcinoma Trials at a Glance

28 actively recruiting trials for metastatic renal cell carcinoma are listed on ClinicalTrialsFinder across 6 cities in 12 countries. The largest study group is Phase 2 with 15 trials, with the heaviest enrollment activity in Houston, Duarte, and Baltimore. Lead sponsors running metastatic renal cell carcinoma studies include M.D. Anderson Cancer Center, Centre Francois Baclesse, and NRG Oncology.

Browse metastatic renal cell carcinoma trials by phase

Treatments under study

About Metastatic Renal Cell Carcinoma Clinical Trials

Looking for clinical trials for Metastatic Renal Cell Carcinoma? There are currently 25 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Metastatic Renal Cell Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Metastatic Renal Cell Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 28 trials

Recruiting
Phase 1Phase 2

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

Metastatic Renal Cell CarcinomaCarcinoma, Renal CellAdvanced Renal Cell Carcinoma+8 more
Pfizer224 enrolled49 locationsNCT07227415
Recruiting
Phase 2

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

Endometrial CancerLocally Advanced Malignant Solid NeoplasmMetastatic Malignant Solid Neoplasm+10 more
Rahul Aggarwal89 enrolled3 locationsNCT03682289
Recruiting
Not Applicable

Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial

Metastatic Malignant Solid NeoplasmMetastatic MelanomaMetastatic Renal Cell Carcinoma+15 more
M.D. Anderson Cancer Center40 enrolled1 locationNCT04693377
Recruiting
Phase 1Phase 2

A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)

Metastatic Renal Cell CarcinomaTranslocation Renal Cell Carcinoma
Memorial Sloan Kettering Cancer Center43 enrolled8 locationsNCT06835972
Recruiting
Phase 2

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

Metastatic Renal Cell CarcinomaStage III Renal Cell Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8+1 more
NRG Oncology240 enrolled318 locationsNCT05327686
Recruiting
Phase 3

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast CarcinomaMetastatic Lung Non-Small Cell Carcinoma+7 more
NRG Oncology269 enrolled263 locationsNCT06500455
Recruiting
Phase 2

Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC

Metastatic Renal Cell CarcinomaAdvanced Renal Cell CarcinomaClear Cell Renal Cell Carcinoma
Karie Runcie70 enrolled2 locationsNCT06863311
Recruiting
Phase 2

Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations

Metastatic Renal Cell CarcinomaRenal Cell CarcinomaKidney Cancer+2 more
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins20 enrolled1 locationNCT03786796
Recruiting
Phase 2

A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma

Metastatic Renal Cell CarcinomaRenal Cell CarcinomaKidney Cancer+3 more
Stephanie Berg25 enrolled2 locationsNCT07123090
Recruiting
Not Applicable

Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and Metastatic Kidney Cancer

Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Renal Cell CarcinomaStage IV Renal Cell Cancer AJCC v8+1 more
Ohio State University Comprehensive Cancer Center60 enrolled1 locationNCT06391099
Recruiting
Phase 1Phase 2

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma+97 more
Mayo Clinic132 enrolled1 locationNCT05269381
Recruiting
Phase 2

Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma

Metastatic MelanomaMetastatic Renal Cell CarcinomaAdvanced Locoregional Melanoma+1 more
National Cancer Institute (NCI)78 enrolled1 locationNCT05155033
Recruiting
Phase 1

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

Malignant Solid NeoplasmAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+71 more
M.D. Anderson Cancer Center43 enrolled1 locationNCT05092373
Recruiting
Phase 2

A Randomized Trial of Maintenance Systemic Therapy After Radiation for Oligometastatic Renal Cell Carcinoma (ASTROs)

Oligometastatic Renal Cell Carcinoma
M.D. Anderson Cancer Center144 enrolled1 locationNCT06004336
Recruiting
Phase 2

A Phase II Study Assessing Stereotactic Radiotherapy in Therapeutic Strategy of Oligoprogressive Renal Cell Carcinoma Metastases

Metastatic Renal Cell CarcinomaRadiotherapy
Centre Francois Baclesse77 enrolled30 locationsNCT04299646
Recruiting
Phase 2

Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma

Metastatic Renal Cell CarcinomaRenal Cell CarcinomaOligoprogressive+1 more
Yale University30 enrolled1 locationNCT04974671
Recruiting
Phase 2

Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

Metastatic Renal Cell CarcinomaNeuroendocrine TumorsCarcinoid Tumor+1 more
Fox Chase Cancer Center111 enrolled1 locationNCT05263050
Recruiting

International Multicentric Study ARON-1

Metastatic Renal Cell Carcinoma (mRCC)
Hospital of Macerata1,220 enrolled1 locationNCT05287464
Recruiting
Phase 4

Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal Carcinoma

Metastatic Renal Cell CarcinomaLocally AdvancedRenal Cell Carcinoma (Kidney Cancer)
Centre Francois Baclesse83 enrolled10 locationsNCT07028125
Recruiting
Phase 2

PET/CT-Directed Free of Therapy for Metastatic RCC Patients With IMDC Favorable or Intermediate Risk

Renal Cell Carcinoma (RCC)Metastatic Renal Cell Carcinoma (mRCC)
Jinling Hospital, China30 enrolled1 locationNCT07175480